Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Universität Hamburg · University of Cologne · +30 more institutions
Abstract
amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.
amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the cohort assignments.
Citation impact
- FWCI
- 67.77
- Percentile
- 100%
- References
- 49
Authors
32- JWJürgen WolfCorresponding
Universität Hamburg, University of Cologne, Heidelberg University, University Hospital Heidelberg, Integrated Oncology (United States), University Medical Center Hamburg-Eppendorf, University Hospital Cologne
- TSTakashi Seto
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, National Hospital Organization Kyushu Cancer Center, University Medical Center Hamburg-Eppendorf
- JHJi‐Youn Han
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, National Cancer Center
- NRNoemı́ Reguart
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Hospital Clínic de Barcelona
- EBEdward B. Garon
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf
Topics & keywords
- Exon
- Lung cancer
- Cancer research
- Mutation
- Cancer
- Biology
- Internal medicine
- Oncology
- Good health and well-being